Optical Imaging in X-linked Disorders.

Recruiting N/A Interventional Study
Fragile X Syndrome (FXS) Creatine Transporter Deficiency
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 – 60
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
118 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Fragile X syndrome (FXS, OMIM #300624) and Creatine Transporter Deficiency (CTD, #300352) are the two most common causes of X-linked intellectual disability. FXS and CTD affect hemizygous males and with highly variable severity heterozygous females. Both these neurodevelopmental disorders (NDDs) have a dramatic impact on the family quality of life and the health-care system. These disorders share …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria : CTD male patients : * male * having a confirmed mutation in the SLC6A8 gene * ≥ 5 to ≤ 35 years old * whose maternal language is French, * having signed the informed consent and/or for whom parents (for children)/legal guardian (for protected adults) have signed the informed c…
Contacts

Aurore CURIE, Dr

+336 70 62 69 76

Aurore.curie@chu-lyon.fr

CONTACT